Esperion Therapeutics Management
Management criteria checks 3/4
Esperion Therapeutics' CEO is Sheldon Koenig, appointed in May 2021, has a tenure of 3.58 years. total yearly compensation is $2.97M, comprised of 24.3% salary and 75.7% bonuses, including company stock and options. directly owns 0.14% of the company’s shares, worth $592.61K. The average tenure of the management team and the board of directors is 2.8 years and 3.4 years respectively.
Key information
Sheldon Koenig
Chief executive officer
US$3.0m
Total compensation
| CEO salary percentage | 24.3% |
| CEO tenure | 3.6yrs |
| CEO ownership | 0.1% |
| Management average tenure | 2.8yrs |
| Board average tenure | 3.4yrs |
Recent management updates
Recent updates
Will The Long Awaited Breakout For Esperion Therapeutics Hold?
Dec 08Esperion Therapeutics: Growth Initiatives Are Paying Off - Buy
Nov 13Esperion Therapeutics: Strategically Positioned To Grow
Aug 16Buy Esperion Therapeutics Despite An Abiding Skepticism Weighing On The Stock
May 20A Relief Earnings Report Ahead Of An Inflection Point For Esperion Therapeutics
Feb 28Navigating Esperion Therapeutics' Surprise Secondary Offering: Some Investment Considerations
Jan 22Esperion Is Sitting On A Potential Blockbuster Drug
Jan 14Many Still Looking Away From Esperion Therapeutics, Inc. (NASDAQ:ESPR)
Jun 19
Upgrade: Analysts Just Made A Substantial Increase To Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Forecasts
Mar 09Analysts Have Just Cut Their Esperion Therapeutics, Inc. (NASDAQ:ESPR) Revenue Estimates By 18%
Feb 23Esperion says Nexletol recommended as oral non-statin therapy for lowering cholesterol
Aug 26Esperion Therapeutics: Positive Update On CLEAR Outcomes Trial Offsets Mixed Q2 Earnings
Aug 09Esperion Therapeutics Q2 2022 Earnings Preview
Aug 01Esperion Therapeutics: 2021 Labors Paying Off In 2022
May 07Esperion Therapeutics: Ready For Growth Ahead Of Clear Outcomes Topline Data Readout
Feb 24CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2024 | n/a | n/a | -US$87m |
| Jun 30 2024 | n/a | n/a | -US$98m |
| Mar 31 2024 | n/a | n/a | -US$87m |
| Dec 31 2023 | US$3m | US$721k | -US$209m |
| Sep 30 2023 | n/a | n/a | -US$208m |
| Jun 30 2023 | n/a | n/a | -US$222m |
| Mar 31 2023 | n/a | n/a | -US$239m |
| Dec 31 2022 | US$4m | US$683k | -US$234m |
| Sep 30 2022 | n/a | n/a | -US$243m |
| Jun 30 2022 | n/a | n/a | -US$258m |
| Mar 31 2022 | n/a | n/a | -US$235m |
| Dec 31 2021 | US$8m | US$566k | -US$269m |
| Sep 30 2021 | n/a | n/a | -US$308m |
| Jun 30 2021 | n/a | n/a | -US$325m |
| Mar 31 2021 | n/a | n/a | -US$156m |
| Dec 31 2020 | US$508k | US$23k | -US$144m |
Compensation vs Market: Sheldon's total compensation ($USD2.97M) is above average for companies of similar size in the US market ($USD2.16M).
Compensation vs Earnings: Sheldon's compensation has been consistent with company performance over the past year.
CEO
Sheldon Koenig (58 yo)
3.6yrs
Tenure
US$2,968,565
Compensation
Mr. Sheldon L. Koenig has been President, Chief Executive Officer and Director at Esperion Therapeutics, Inc. since May 17, 2021 and had been its Chief Operating Officer since December 15, 2020 until May 1...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.6yrs | US$2.97m | 0.14% $ 592.6k | |
| Chief Commercial Officer | 2.8yrs | US$1.08m | 0.081% $ 344.3k | |
| Chief Financial Officer | 2.1yrs | no data | 0.12% $ 517.5k | |
| Chief Technical Operations Officer | 1.9yrs | no data | no data | |
| General Counsel & Corporate Secretary | 2.9yrs | US$1.29m | 0.093% $ 394.9k | |
| Associate Director of Corporate Communications | no data | no data | no data | |
| Chief Business Officer | no data | no data | no data |
2.8yrs
Average Tenure
52yo
Average Age
Experienced Management: ESPR's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | 3.6yrs | US$2.97m | 0.14% $ 592.6k | |
| Lead Independent Director | 16.7yrs | US$94.78k | 0.016% $ 68.3k | |
| Independent Non-Employee Director | 4.8yrs | US$104.78k | 0.027% $ 114.8k | |
| Independent Director | 10.9yrs | US$82.28k | 0.026% $ 110.9k | |
| Independent Director | 6.6yrs | US$97.28k | 0.026% $ 110.9k | |
| Independent Director | 2.7yrs | US$94.78k | 0.018% $ 77.9k | |
| Independent Chairperson | 2.5yrs | US$117.28k | 0.033% $ 139.0k | |
| Member of Scientific Advisory Board | 2.3yrs | no data | no data | |
| Independent Director | 3.2yrs | US$99.78k | 0.014% $ 60.5k | |
| Independent Director | 5.6yrs | US$91.97k | 0.014% $ 61.1k | |
| Member of Scientific Advisory Board | 2.3yrs | no data | no data | |
| Member of Scientific Advisory Board | 2.3yrs | no data | no data |
3.4yrs
Average Tenure
67yo
Average Age
Experienced Board: ESPR's board of directors are considered experienced (3.4 years average tenure).
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/12/31 03:42 |
| End of Day Share Price | 2024/12/31 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Esperion Therapeutics, Inc. is covered by 19 analysts. 8 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Zemansky | BofA Global Research |
| Thomas Shrader | BTIG |
| Kristen Kluska | Cantor Fitzgerald & Co. |